The prediction of ΔeGFR for the RASi-only set of patients is the composite biomarker ΔR, which will allow the physician to estimate ΔeGFR within the next year (and thus the state of CD or UCD) in case the patient remains on RASi only. This evidence concerns the gene MMP19 and urea cycle disorder.